PRGO Earnings Date: Nov 4, 2026 (Estimated) — Perrigo Company plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is PRGO's next earnings date?
Perrigo Company plc (PRGO) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.51 on revenue of $984.8M.
How did PRGO do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Perrigo Company plc posted EPS of $0.50 versus the $0.39 estimate, a beat of 38.9%. Revenue was $1.02B against a $1.02B estimate. The stock's 1-day post-earnings move was +23.1%.
How much does PRGO stock move after earnings?
PRGO beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.1% (up or down) in the day after earnings.
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.39 | 0.50 | +38.89% | $1.02B | ✅ Beat | +23.07% | +19.21% | +36.44% |
| 2026-05-06 | Q1 2026 | 0.33 | 0.43 | +30.30% | $939.0M | ✅ Beat | +5.24% | -4.53% | -6.58% |
| 2026-02-26 | Q4 2025 | 0.79 | 0.77 | -2.53% | $1.14B | ❌ Miss | -1.53% | -17.53% | -33.81% |
| 2025-11-05 | Q3 2025 | 0.76 | 0.80 | +5.26% | $1.04B | ✅ Beat | -25.17% | -29.15% | -32.06% |
| 2025-08-06 | Q2 2025 | 0.59 | 0.57 | -3.39% | $1.06B | ❌ Miss | -11.31% | -13.34% | -11.72% |
| 2025-02-27 | Q4 2024 | 0.92 | 0.93 | +1.09% | $1.14B | ✅ Beat | +20.18% | +18.86% | +17.18% |
| 2024-11-06 | Q3 2024 | 0.82 | 0.81 | -1.22% | $1.09B | ❌ Miss | +7.76% | +4.01% | +12.98% |
| 2024-08-02 | Q2 2024 | 0.51 | 0.53 | +3.92% | $1.07B | ✅ Beat | -2.13% | -0.95% | +4.03% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY25 · $1.11B total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| Consumer Self-Care Americas | 62.8% | $697.0M | -6.3% | $634.1M | $671.3M | $744.2M | $620.7M |
| Consumer Self-Care International | 37.2% | $412.6M | +4.7% | $431.3M | $416.3M | $394.1M | $423.1M |
By region
Q2 FY26 · $1.03B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 60.8% | $626.4M | +2.5% | $732.3M | $609.3M | $610.9M | $635.3M |
| Europe | 36.1% | $371.7M | -11.9% | $379.2M | $412.3M | $421.7M | $384.0M |
| Other Geographical Areas | 2.4% | $24.7M | +4.2% | $26.8M | $22.3M | $23.7M | $24.0M |
| IRELAND | 0.7% | $7.7M | -21.4% | $12.8M | $11.0M | $9.8M | $8.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.